#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liver abscess Necrotising myositis Neurodermatitis Deafness neurosensory ROHHAD syndrome Extra-osseous Ewing's sarcoma recurrent B-cell small lymphocytic lymphoma recurrent Neuroblastoma Glycogen storage disease type V Propionic acidaemia Pneumonia Systemic candida Ataxia telangiectasia Ovarian cancer Polycystic liver disease More trials…

    Learn about Rare Diseases

    Haemophagocytic lymphohistiocytosis Bronchiolitis obliterans syndrome – Basic Information Vascular malformation Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Primary immunodeficiency syndrome – Diagnostics Lysosomal storage disorder – Trials in Disease Choroid melanoma – Trials in Disease Krabbe’s disease – Basic Information Brain stem glioma – Life with Disease Amyotrophic lateral sclerosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Omo-103 Trometamol Piperacillin Monohydrate Sotorasib Tumour Detection Iph6501 Corticosteroids, Plain HEMOPEXIN, HUMAN Vepdegestrant Apl-101 Metoprolol Tartrate Immunoglobulin A Bevacizumab Zirconium Zr-89 10-1074-Ls Amikacin Sulfate Gskvx000000014593 Octocog Alfa LY3537031 Dapagliflozin DICLOFENAC POTASSIUM More therapies…

    Learn about Your Condition

    Congenital ureteric anomaly Hairy cell leukaemia recurrent Cutaneous T-cell lymphoma Factor VIII deficiency Muscle strain Drug use disorder Arrhythmia supraventricular Becker's muscular dystrophy Biliary tract operation Metastatic malignant melanoma Partial seizures Enteritis Stomatitis Osteomyelitis Leukocyte adhesion deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell lymphoma recurrent

  • Study on Axicabtagene Ciloleucel for Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    Investigated Drugs:
    • Axicabtagene Ciloleucel
    • Fludarabine
    • Cyclophosphamide
    Spain

  • Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Zamtocabtagene Autoleucel
    • Cyclophosphamide
    • Tocilizumab
    France Germany Italy The Netherlands

  • Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Polatuzumab Vedotin
    • Zamtocabtagene Autoleucel
    Austria Belgium Croatia Czechia Finland France +9

  • Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

    Recruiting

    1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    Investigated Drugs:
    • Mb-Cart20.1
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    • Zamtocabtagene Autoleucel
    Germany

  • Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • 5,6-Dibromo-4-Nitro-2-Piperidin-4-Yl-1-Propan-2-Ylbenzimidazole
    • Glofitamab
    • Obinutuzumab
    France Poland Spain

  • Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Etoposide Phosphate
    • Loncastuximab Tesirine
    • Odronextamab
    Austria Belgium France The Netherlands Spain Sweden
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!